Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · PANCHSHEEL ORGANICS LTD. · 31 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
PANCHSHEEL ORGANICS LTD.
BSE: 531726
BSE: 531726
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
PANCHSHEEL ORGANICS LTD.
StateQ4 FY26 filed
Last close · 30 Oct 2026₹99.50
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA8.1 · 0.93 · 9.9
PANCHSHEEL ORGANICS LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 69 | 103 | 105 | 107 | 107 |
| EBITDA (ex other income) | 13 | 20 | 19 | 18 | 14 |
| margin % | 18.6 | 19.4 | 18.0 | 16.4 | 12.7 |
| Owners' profit | 8 | 14 | 14 | 14 | 11 |
| EPS, as reported (₹) | 8.33 | 12.78 | 11.88 | 20.94 | 8.22 |
| ROE % · ROCE % | 17.6 · 22.7 | 14.6 · 19.8 | 11.3 · 15.2 | 10.3 · 13.3 | 7.7 · 10.1 |
| Debt / equity (x) | 0.09 | 0.06 | 0.05 | 0.04 | 0.04 |
| Cash from operations | (2) | 0 | 10 | 4 | 10 |
| Capex | (2) | 0 | (10) | (16) | (7) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · PANCHSHEEL ORGANICS LTD. · 31 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 27 | 26 | 28 | 24 | 25 | 27 | 31 |
| Profit before tax | 5 | 5 | 5 | 4 | 4 | 3 | 4 | 3 |
| Net profit | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 2 |
| EPS (₹) | 2.60 | 5.76 | 5.58 | 4.82 | 4.32 | 3.96 | 2.79 | 1.29 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,26,524 | 38.9 | 4.76 | 23.7 | 5.5 | 8.0 | 11.8 | 29.3 |
| DIVI S LABORATORIES LTD | 2,59,170 | 88.7 | 15.46 | 75.3 | 15.3 | 18.8 | 8.7 | 40.7 |
| TORRENT PHARMACEUTICALS L | 1,75,309 | 77.9 | 9.54 | 41.5 | 6.0 | 4.0 | 11.8 | 33.5 |
| LAURUS LABS LIMITED | 1,29,969 | 96.9 | 21.03 | 74.4 | 12.9 | 14.2 | 7.2 | 34.0 |
| ZYDUS LIFESCIENCES LTD | 1,24,301 | 27.8 | 4.20 | 15.9 | 17.3 | 18.0 | 12.4 | 24.1 |
| DR. REDDY S LABORATORIES | 1,12,892 | 40.2 | 2.89 | 18.2 | 3.4 | 4.2 | 12.1 | 19.9 |
| CIPLA LTD | 1,11,394 | 38.4 | 3.14 | 18.8 | 4.6 | 6.2 | 8.0 | 18.7 |
| MANKIND PHARMA LIMITED | 1,02,953 | 45.9 | 5.77 | 30.1 | 7.2 | 7.3 | — | 27.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 8.1 | 29.9 | 13 of 160 | 93% |
| P/B | 0.9 | 2.9 | 21 of 163 | 87% |
| ROCE | 9.9 | 9.2 | 83 of 182 | 55% |
| ROE | 7.7 | 7.8 | 85 of 165 | 49% |
| Debt / Equity | 0.0 | 0.1 | 62 of 166 | 63% |
| EBITDA margin | 7.8 | 13.8 | 120 of 177 | 32% |
| Revenue growth | 9.5 | 17.1 | 98 of 161 | 39% |
| Profit growth | (46.3) | 27.3 | 132 of 158 | 17% |
| Market cap | 131 | 802 | 124 of 181 | 32% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · PANCHSHEEL ORGANICS LTD. · 31 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 24 Oct 2026 · Board approves application to NSE for direct listing | capital market events | medium | — | — |
| 24 Oct 2026 · Board approves direct listing of existing shares on NSE Main Board | capital market events | medium | — | — |
| 6 Oct 2026 · Reg 74(5) compliance certificate for Q1 FY27, no shares dematerialised | compliance | minimal | — | — |
| 5 Oct 2026 · Board changes and statutory auditor appointment at 37th AGM | management changes | medium | — | — |
| 5 Oct 2026 · Board reshuffle: new MD, promoter family entry, new auditor appointed | management changes | medium | — | — |
| 3 Oct 2026 · 37th AGM: all 7 resolutions passed with 99.97 percent support | compliance | minimal | — | — |
| 30 Sept 2026 · Panchsheel Organics 37th AGM: 7 resolutions passed, dividend approved | board shareholder meetings | low | — | — |
| 28 Sept 2026 · Trading window closed ahead of Q2 FY27 results | compliance | minimal | — | — |
| 9 Sept 2026 · Notice of 37th AGM published in newspapers | compliance | minimal | — | — |
| 8 Sept 2026 · AGM on 30 Sep via video conference; Record Date 23 Sep for Final Dividend | corporate actions | high | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in